secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001193125-25-155811
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Cogent reports positive top-line results from SUMMIT trial of bezuclastinib in non-advanced systemic mastocytosis
--------------------------------------------------------------------------------

- SUMMIT Part 2 met primary endpoint with highly significant mean TSS reduction of 24.3 points vs placebo 15.4 (p=0.0002) at 24 weeks.
- 87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% on placebo (p<0.0001).
- All key secondary endpoints achieved statistical significance, including KIT D816V VAF and bone marrow MC aggregates reductions.
- Company on track to submit NDA to FDA for bezuclastinib in NonAdvSM by end of 2025; detailed results planned for medical meeting.
- Safety profile manageable: most TEAEs low grade, discontinuations due to ALT/AST elevations (5.9%) all resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/0001193125-25-155811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-155811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer